BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High – Here’s What Happened

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $84.06 and last traded at $79.8380, with a volume of 788746 shares changing hands. The stock had previously closed at $73.33.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 met its primary endpoint (AHV) with a mean treatment difference vs. placebo of +2.10 cm/year; key secondary measures (height Z-score, body proportionality in <8-year-olds) also improved and safety was clean — company plans NDA/MAA submissions H2 2026. BridgeBio Reports Positive Phase 3 Topline Results
• Positive Sentiment: Market reaction: multiple outlets report BBIO stock jumped on the infigratinib readout while rivals (e.g., BioMarin, Ascendis) fell — the data appear to change the competitive landscape for achondroplasia treatments. BridgeBio stock jumps after positive Phase 3 results
• Neutral Sentiment: Short-interest reports in feeds show anomalous/zero values for February (likely data/reporting artifact) and do not provide a clear signal about bearish positioning right now.
• Negative Sentiment: Zacks warns BridgeBio may report negative earnings in the upcoming quarter and lacks setup for an earnings beat; near-term EPS weakness or guidance shortfalls could weigh on the stock despite the clinical win. BridgeBio Pharma (BBIO) May Report Negative Earnings
• Negative Sentiment: Quiver/other data note heavy insider selling activity in recent periods — a potential governance/stock-sentiment negative that investors may watch, even though the clinical news is currently dominant. QuiverQuant PROPEL 3 summary & insider notes

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BBIO shares. Raymond James Financial restated an “outperform” rating and issued a $71.00 price objective (up from $69.00) on shares of BridgeBio Pharma in a report on Thursday, October 30th. Wells Fargo & Company increased their target price on BridgeBio Pharma from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Morgan Stanley assumed coverage on BridgeBio Pharma in a research report on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 target price for the company. Evercore reissued an “outperform” rating on shares of BridgeBio Pharma in a research report on Monday, October 27th. Finally, Barclays began coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 28th. They issued an “overweight” rating for the company. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.05.

BridgeBio Pharma Price Performance

The company has a market cap of $14.91 billion, a PE ratio of -18.52 and a beta of 1.13. The business’s 50 day moving average is $75.54 and its 200-day moving average is $62.79.

Insider Activity

In other news, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $66.65, for a total transaction of $666,500.00. Following the completion of the sale, the director owned 11,589 shares in the company, valued at approximately $772,406.85. The trade was a 46.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Andrew Lo sold 55,000 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total transaction of $3,612,950.00. Following the completion of the transaction, the director directly owned 50,583 shares in the company, valued at $3,322,797.27. This trade represents a 52.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 260,700 shares of company stock valued at $18,157,071 over the last 90 days. Insiders own 18.20% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently bought and sold shares of BBIO. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma in the 1st quarter valued at about $35,000. KLP Kapitalforvaltning AS increased its position in BridgeBio Pharma by 20.1% during the second quarter. KLP Kapitalforvaltning AS now owns 28,035 shares of the company’s stock worth $1,211,000 after buying an additional 4,700 shares during the period. Vontobel Holding Ltd. purchased a new stake in BridgeBio Pharma in the second quarter valued at approximately $424,000. Vanguard Personalized Indexing Management LLC lifted its stake in BridgeBio Pharma by 5.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 16,178 shares of the company’s stock valued at $699,000 after buying an additional 772 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of BridgeBio Pharma by 29.8% in the second quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after acquiring an additional 1,569 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.